Mayo Clinic Laboratory and Pathology Research Roundup: April 23

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.

Only 20 percent of renal and bladder cancer patients will show a significant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response. We developed an "immunotumoroid" cell model system that recapitulates the tumor, its microenvironment, and necessary immune system components in patient-derived spheroids to enable ex vivo assessment of tumor response to ICI therapy.

Read more.

Published to PubMed This Week

Sarah Jarvis

Sarah Jarvis is a Senior Marketing Specialist at Mayo Clinic Laboratories. She supports marketing strategies for paid media.